| Hypertensive disease

Cleviprex vs Katerzia

Side-by-side clinical, coverage, and cost comparison for hypertensive disease.

Deep comparison between: Cleviprex vs Katerzia with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsKaterzia has a higher rate of injection site reactions vs Cleviprex based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Katerzia but not Cleviprex, including UnitedHealthcare

Category

Cleviprex

Katerzia

At A Glance

RouteIV infusion

FrequencyContinuous infusion

ClassDihydropyridine CCB

RouteOral

FrequencyDaily

ClassCalcium channel blocker

Indications

Hypertensive disease

Hypertensive disease
Stable angina
Angina Pectoris, Variant
Coronary Artery Disease

Dosing

Hypertensive disease Initiate IV infusion at 1-2 mg/hour; double dose at 90-second intervals initially, then increase by less than doubling every 5-10 minutes as goal blood pressure is approached; maintenance 4-6 mg/hour; maximum 16 mg/hour (up to 32 mg/hour for severe hypertension); lipid load limit 1000 mL or an average of 21 mg/hour per 24 hours.

Hypertensive disease (adults) 5 mg orally once daily (max 10 mg); start 2.5 mg in small, fragile, elderly patients, or those with hepatic insufficiency.

Hypertensive disease (pediatric, ages 6-17) 2.5-5 mg orally once daily; doses >5 mg have not been studied in pediatric patients.

Stable angina, Angina Pectoris, Variant 5-10 mg orally once daily; lower dose suggested in elderly and patients with hepatic insufficiency; most patients require 10 mg.

Coronary Artery Disease 5-10 mg orally once daily; majority of patients required 10 mg in clinical studies.

Contraindications

Allergy to soybeans, soy products, eggs, or egg products
Defective lipid metabolism such as pathologic hyperlipemia, lipoid nephrosis, or acute pancreatitis accompanied by hyperlipidemia
Severe aortic stenosis

Known sensitivity to amlodipine

Drug Interactions

1074View drug interactions

1162View drug interactions

Adverse Reactions

Most common Headache, nausea, vomiting, acute renal failure, atrial fibrillation

Serious Myocardial infarction, cardiac arrest, syncope, dyspnea

Postmarketing Increased blood triglycerides, ileus, hypersensitivity, hypotension, nausea, decreased oxygen saturation, reflex tachycardia

Most common (>1%) edema, dizziness, flushing, palpitation, fatigue, nausea, abdominal pain, somnolence

Postmarketing gynecomastia, jaundice, hepatic enzyme elevations, extrapyramidal disorder

Pharmacology

Clevidipine is a dihydropyridine L-type calcium channel blocker that lowers blood pressure by inhibiting calcium influx in arterial smooth muscle, reducing systemic vascular resistance without affecting venous preload or cardiac filling pressure.

Amlodipine is a dihydropyridine calcium channel blocker that inhibits transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, causing peripheral arterial vasodilation, reduction in peripheral vascular resistance, and reduction in blood pressure.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Cleviprex